How Can Advanced Imaging Studies Enhance Diabetes Management?
New approaches to applying noninvasive imaging tests such as computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) may play a bigger role in evaluating and managing patients with diabetes. Advances in noninvasive imaging technology can assess important changes in fat composition and distribution in the body that may affect the metabolic complications and diseases associated with diabetes, including cardiovascular disease and cancer. A forward-looking Review article on “Obesity and Diabetes: Newer Concepts in Imaging” in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, highlights these emerging advances. The article is available on the Diabetes Technology & Therapeutics website.
Kavita Garg, MD, Samuel Chang, MD, and Ann Scherzinger, PhD, University of Colorado Denver School of Medicine, Aurora, describe how sophisticated imaging techniques can be used to quantify body fat in different locations in the body. It can also help distinguish between different types of fat, which can have different effects on metabolism and pose different disease risks. In their Review article, the authors suggest that noninvasive imaging tests may be able to replace the need for biopsies, aid in early disease detection, and identify not only structural but also functional abnormalities in tissues such as heart muscle before a disorder becomes symptomatic.
“Currently, imaging techniques are not routinely done in people with diabetes,” says Viswanathan Mohan, MD, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control and IDF Centre for Education, Gopalapuram, Chennai, India, in his accompanying Editorial, “Has the Time Come for Routine Imaging Studies in Diabetes?” With the changing profile of the complications of diabetes and increased incidence of diseases related to diabetes and diabetes therapies, “the article by Garg et al. is a trend-setter because this could change the way we routinely screen for these conditions in people with diabetes.”
About the Journal
Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website.
Diabetes affects 25.8 million people of all ages
8.3 percent of the U.S. population
DIAGNOSED - 18.8 million people
UNDIAGNOSED - 7.0 million people
Among U.S. residents ages 65 years and older, 10.9 million, or 26.9 percent, had diabetes in 2010.
About 215,000 people younger than 20 years had diabetes - type 1 or type 2 - in the United States in 2010.
About 1.9 million people ages 20 years or older were newly diagnosed with diabetes in 2010 in the United States.
In 2005–2008, based on fasting glucose or hemoglobin A1C (A1C) levels, 35 percent of U.S. adults ages 20 years or older had prediabetes - 50 percent of adults ages 65 years or older. Applying this percentage to the entire U.S. population in 2010 yields an estimated 79 million American adults ages 20 years or older with prediabetes.
Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputations, and new cases of blindness among adults in the United States.
Diabetes is a major cause of heart disease and stroke.
Diabetes is the seventh leading cause of death in the United States.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
###
Contact: Vicki Cohn, (914) 740-2156, .(JavaScript must be enabled to view this email address)